Palbace 125 Mg

Palbace 125 mg

Description: Palbace 125 mg is an oral medication used in the treatment of breast cancer. It contains Palbociclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that impedes the progression of cancer cells through the cell cycle. Palbace is primarily prescribed for hormone receptor-positive, HER2-negative metastatic breast cancer, often in combination with hormone therapies.

Salt Composition:

• Palbociclib (125 mg): A selective CDK4/6 inhibitor that blocks the activity of cyclin-dependent kinases, thus slowing down cancer cell proliferation.

Key Features:

• Selective Inhibition: Targets CDK4/6 to disrupt cancer cell cycle progression.
• Oral Dosage: Administered in tablet form for ease of use.
• Combination Therapy: Used alongside other treatments such as letrozole or aromatase inhibitors.

Benefits:

• Controls Cancer Growth: Effective in managing hormone receptor-positive metastatic breast cancer.
• Improves Treatment Outcomes: Enhances the efficacy of hormone therapies and helps in prolonging disease control.
• Convenient Administration: Oral tablets provide a user-friendly option for ongoing treatment.

American Brand Names:

• Ibrance

Indian Brand Names:

• Palbace 125 mg
• Ibrance

Related Keywords: Palbace 125 mg, Palbociclib, CDK4/6 inhibitor, metastatic breast cancer, hormone receptor-positive breast cancer, oral cancer medication, Ibrance, targeted cancer therapy.